Baclofen in the Treatment of Muscle Cramps in Patients With Cirrhosis

Sponsor
Tanta University (Other)
Overall Status
Unknown status
CT.gov ID
NCT02221570
Collaborator
(none)
100
1
2
5
19.9

Study Details

Study Description

Brief Summary

Patients with cirrhosis often experience muscle cramps with varying severity. The mechanism of their occurrence is not yet understood. Muscle cramps in patients with cirrhosis are associated with significantly diminished quality of life.

The aim of the study is to assess the efficacy of baclofen in the treatment of muscle cramps in patients with liver cirrhosis.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Muscle cramps are common in patients with liver disease and associated with significantly diminished quality of life. Patients with cirrhosis often experience muscle cramps with varied frequency and severity. The exact mechanisms by which they occur remain unclear, although a number of pathophysiological events unique to liver disease may contribute. Clinical studies have identified alterations in 3 areas: nerve function, energy metabolism, and plasma volume/electrolytes.

Although a number of mechanisms for cramps in liver disease have been postulated and have been targeted by medical therapies, a clear picture of the causal events has not emerged. Several agents as vitamin E, human albumin, zinc, taurine, eperisone hydrochloride and branched-chain amino acids have shown some benefit in small uncontrolled studies, although large randomized controlled trials are lacking.

Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.

The aim of the study is to assess the efficacy of baclofen in the treatment of muscle cramps in patients with liver cirrhosis.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
A Randomized Placebo Controlled Study of Baclofen in the Treatment of Muscle Cramps in Patients With Cirrhosis
Study Start Date :
Jun 1, 2014
Anticipated Primary Completion Date :
Nov 1, 2014
Anticipated Study Completion Date :
Nov 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Baclofen

Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.

Drug: Baclofen
Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
Other Names:
  • Gablofen
  • Lioresal
  • Apo-Baclofen
  • Dom-Baclofen
  • Liotec
  • Med-Baclofen
  • Mylan-Baclofen
  • Novo-Baclofen
  • Nu-Baclo
  • PHL-Baclofen
  • PMS-Baclofen
  • ratio-Baclofen
  • Riva-Baclofen
  • Placebo Comparator: Placebo

    placebo of baclofen

    Outcome Measures

    Primary Outcome Measures

    1. Percentage of participants with decreased incidence of muscle cramps after taking Baclofen compared with placebo. [3 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Cirrhosis

    • Muscle cramps( ≥3 cramps per week )

    Exclusion Criteria:
    • Allergy to baclofen

    • Renal impairment

    • Pregnant and lactating women

    • Peripheral vascular disease

    • Peripheral neuropathy

    • Medications as calcium channel blockers, conjugated estrogens and naproxen.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Tanta University Hospital Tanta Gharbia Egypt

    Sponsors and Collaborators

    • Tanta University

    Investigators

    • Principal Investigator: Asem A Elfert, MD, Tanta Faculty of Medicine, Professor
    • Study Director: Lobna A AboAli, Tanta Faculty of Medicine, Lecturer
    • Study Director: Samah M Soliman, Tanta Faculty of Medicine, Lecturer
    • Study Director: Ibrahim Shebl, Tanta University Hospitals, House Officer

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Ibrahim Shebl, Dr., Tanta University
    ClinicalTrials.gov Identifier:
    NCT02221570
    Other Study ID Numbers:
    • baclofen cramps
    First Posted:
    Aug 20, 2014
    Last Update Posted:
    Oct 6, 2014
    Last Verified:
    Oct 1, 2014
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 6, 2014